Matthias Heinzel - Merck KGaA CEO Board
| MRK Stock | 137.85 0.25 0.18% |
Insider
Matthias Heinzel is CEO Board of Merck KGaA
| Age | 56 |
| Phone | 49 6151 72 0 |
| Web | https://www.merckgroup.com |
Merck KGaA Management Efficiency
The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck KGaA's management efficiency ratios could be used to measure how well Merck KGaA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Craig Johnstone | Evotec SE | 53 | |
| Anja Bosler | Evotec SE | N/A | |
| Muthusamy RPh | ANI Pharmaceuticals | 55 | |
| Nikhil Lalwani | ANI Pharmaceuticals | 45 | |
| MBA MBA | Evotec SE | 54 | |
| Gabriele Hansen | Evotec SE | N/A | |
| Meredith Cook | ANI Pharmaceuticals | N/A | |
| Christian Dargel | Evotec SE | N/A | |
| Britta Hamberger | Dermapharm Holding SE | N/A | |
| Krista Davis | ANI Pharmaceuticals | N/A | |
| Enno Spillner | Evotec SE | 53 | |
| Monika Conradt | Evotec SE | N/A | |
| Christof Dreibholz | Dermapharm Holding SE | 56 | |
| James Marken | ANI Pharmaceuticals | 60 | |
| Andreas Eberhorn | Dermapharm Holding SE | 48 | |
| Volker Braun | Evotec SE | N/A | |
| Stephen Carey | ANI Pharmaceuticals | 52 | |
| Matthias Evers | Evotec SE | 50 | |
| Christopher Mutz | ANI Pharmaceuticals | 51 | |
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| Chad Gassert | ANI Pharmaceuticals | 47 | |
Management Performance
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 |
Merck KGaA Leadership Team
Elected by the shareholders, the Merck KGaA's board of directors comprises two types of representatives: Merck KGaA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck KGaA's management team and ensure that shareholders' interests are well served. Merck KGaA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck KGaA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Guenter, CEO Board | ||
| Matthias Heinzel, CEO Board | ||
| Dirk Toepfer, Chief Officer | ||
| Barbara Weiland, Chief Officer | ||
| Gerhard Schmitz, Head Accounting | ||
| Belen MD, Chair CEO | ||
| Kai Beckmann, CEO Board | ||
| Marcus Kuhnert, CFO Board | ||
| Constantin Fest, Head Relations | ||
| Friederike Rotsch, Group Compliance |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck KGaA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 87.36 B | |||
| Shares Outstanding | 129.24 M | |||
| Shares Owned By Institutions | 60.26 % | |||
| Price To Book | 2.77 X | |||
| Price To Sales | 3.64 X | |||
| Revenue | 19.69 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Merck Stock Analysis
When running Merck KGaA's price analysis, check to measure Merck KGaA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck KGaA is operating at the current time. Most of Merck KGaA's value examination focuses on studying past and present price action to predict the probability of Merck KGaA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck KGaA's price. Additionally, you may evaluate how the addition of Merck KGaA to your portfolios can decrease your overall portfolio volatility.